SCHEMBL2406119

SCHEMBL2406119

Fc1cccc(NN2CCOCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 6/20 0.46
RAB9A P51151 3/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ENPP2 Q13822 2/20 0.43
CHEK1 O14757 1/20 0.43
ICMT O60725 1/20 0.43
NPC1 O15118 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547476 0.84 ALDH1A1 (0.54) KMT2AMEN1KDM4EALDH1A1RAB9A
SCHEMBL5550694 0.82 ALDH1A1 (0.53) KMT2AMEN1KDM4EALDH1A1RAB9A
Salicyladehyde SCHEMBL28708651 0.82 DDX3X (0.45) KMT2AMEN1KDM4ECYP3A4CYP2D6
SCHEMBL8306103 0.82 KMT2A (0.58) KMT2AMEN1KDM4ECYP3A4CYP2D6
SCHEMBL28533950 0.79 KMT2A (0.49) KMT2AMEN1KDM4ECYP2D6ALDH1A1
SCHEMBL5551984 0.79 ALDH1A1 (0.47) KMT2AMEN1KDM4ECYP3A4CYP2D6
SCHEMBL7550241 0.79 KMT2A (0.54) KMT2ACYP3A4CYP2C19ALDH1A1RAB9A
SCHEMBL10891076 0.79 POLB (0.54) KDM4ECYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL28676055 0.79 ALDH1A1 (0.50) KMT2AMEN1KDM4ECYP2D6CYP2C19
SCHEMBL28933514 0.79 ALDH1A1 (0.36) KMT2AMEN1KDM4ECYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420612-A Target protein degradation compound based on CDK4/6 inhibitor and preparation method and application thereof 沈阳药科大学 2024-08-02 CN claimed
CN-115925647-A Production method of linezolid 湖北广济药业股份有限公司 2023-04-07 CN claimed
CN-114505036-A Method and equipment for preparing linezolid 程竹隐 2022-05-17 CN claimed
CN-108640888-B Double-halogenated salicylaldehyde 3-fluoro-4-morpholinyl aniline Schiff base and preparation method and application thereof 淮阴师范学院 2022-03-15 CN claimed
CN-112409286-A Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone 杭州迪克科技有限公司 2021-02-26 CN claimed
EP-3095777-B1 LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID ZHEJIANG MED XINCHANG PHARM (CN) 2018-06-27 EP claimed
EP-3095777-A1 LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) 2016-11-23 EP claimed
EP-2595968-B1 NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES LEE PHARMA LTD (IN) 2015-09-09 EP claimed
US-8962827-B2 Linezolid intermediate and method for synthesizing linezolid ZHEJIANG MEDICINE CO. LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) 2015-02-24 US claimed
US-20140024827-A1 LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID ZHEJIANG MEDICINE CO., LTD XINCHANG PHARMACEUTICAL FACTORY (CN) 2014-01-23 US claimed
EP-1737850-B1 A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS SYMED LABS LTD (IN) 2007-10-03 EP claimed
CN-119161306-A Bicycloacetamide structural compound, preparation method and pharmaceutical application thereof 河南大学 2024-12-20 CN disclosed
CN-118772064-A Pyrimidine compound containing nitrogen methoxy benzamide and preparation method and application thereof 贵州大学 2024-10-15 CN disclosed
CN-118420612-A Target protein degradation compound based on CDK4/6 inhibitor and preparation method and application thereof 沈阳药科大学 2024-08-02 CN disclosed
CN-118290358-A Method for preparing linezolid key intermediate (S) -5- ((benzylamino) methyl) oxazolidine-2-one 江苏医药职业学院 2024-07-05 CN disclosed
WO-1999037630-A1 OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION VERSICOR, INC. (US) 1999-07-29 WO disclosed
US-5880118-A Substituted oxazine and thiazine oxazolidinone antimicrobials PHARMACIA & UPJOHN COMPANY (US) 1999-03-09 US disclosed
US-5688792-A BACTERICIDES PHARMACIA & UPJOHN COMPANY (US) 1997-11-18 US disclosed
EP-0717738-A1 SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1996-06-26 EP disclosed
WO-1995007271-A1 SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS THE UPJOHN COMPANY (US) 1995-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024827-A1 LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID CYP2C9, CYP3A4, CYP2C19 KMT2A 246/4885MEN1 2309/4885KDM4E 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.